Loading...
•
Dec 31, 2023
Carisma Therapeutics Q4 2023 Earnings Report
Reported financial results for Q4 2023 and provided a business update, prioritizing CT-0525 and restructuring operations.
Key Takeaways
Carisma Therapeutics reported its Q4 and full year 2023 financial results, highlighting the prioritization of CT-0525 and a restructuring plan to extend its cash runway into Q3 2025. The company is focusing on its ex vivo and in vivo oncology programs, as well as research programs including fibrosis.
Prioritizing CT-0525 as anti-HER2 CAR-M product candidate and ceasing further development of CT-0508.
Cash and cash equivalents of $77.6 million as of December 31, 2023, expected to fund operations into the third quarter of 2025.
Reprioritizing pipeline programs on those with the greatest overall potential and near-term milestones.
Implemented a restructuring of operations, including pausing development of CT-1119 and a workforce reduction to reduce expenses and streamline operations.
Carisma Therapeutics
Carisma Therapeutics
Carisma Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenues Revenue
CapyFin.com Forward Guidance
Carisma anticipates that its cash and cash equivalents of $77.6 million as of December 31, 2023, combined with the expected cost savings from implementing the revised operating plan, are sufficient to sustain its planned operations into the third quarter of 2025.